CN100494202C - 螺呋喃并吡啶芳基衍生物 - Google Patents

螺呋喃并吡啶芳基衍生物 Download PDF

Info

Publication number
CN100494202C
CN100494202C CNB2004800311537A CN200480031153A CN100494202C CN 100494202 C CN100494202 C CN 100494202C CN B2004800311537 A CNB2004800311537 A CN B2004800311537A CN 200480031153 A CN200480031153 A CN 200480031153A CN 100494202 C CN100494202 C CN 100494202C
Authority
CN
China
Prior art keywords
furo
pharmaceutically acceptable
disease
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800311537A
Other languages
English (en)
Chinese (zh)
Other versions
CN1871241A (zh
Inventor
艾菲恩·菲利普斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1871241A publication Critical patent/CN1871241A/zh
Application granted granted Critical
Publication of CN100494202C publication Critical patent/CN100494202C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB2004800311537A 2003-10-21 2004-10-21 螺呋喃并吡啶芳基衍生物 Expired - Fee Related CN100494202C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51289303P 2003-10-21 2003-10-21
US60/512,893 2003-10-21

Publications (2)

Publication Number Publication Date
CN1871241A CN1871241A (zh) 2006-11-29
CN100494202C true CN100494202C (zh) 2009-06-03

Family

ID=34549233

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800311537A Expired - Fee Related CN100494202C (zh) 2003-10-21 2004-10-21 螺呋喃并吡啶芳基衍生物

Country Status (13)

Country Link
US (1) US7544693B2 (enExample)
EP (1) EP1678183A1 (enExample)
JP (1) JP4855264B2 (enExample)
KR (1) KR20060094962A (enExample)
CN (1) CN100494202C (enExample)
AU (1) AU2004285751B2 (enExample)
BR (1) BRPI0415546A (enExample)
CA (1) CA2543436A1 (enExample)
IL (1) IL174700A0 (enExample)
MX (1) MXPA06004299A (enExample)
NO (1) NO20062307L (enExample)
NZ (1) NZ546413A (enExample)
WO (1) WO2005042538A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018210229A1 (zh) * 2017-05-18 2018-11-22 南京明德新药研发股份有限公司 α-7尼古丁乙酰胆碱受体激动剂及应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005022788A1 (de) * 2005-05-12 2006-11-23 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2019082143A1 (en) 2017-10-27 2019-05-02 Fresenius Kabi Oncology Ltd. IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1270592A (zh) * 1997-07-18 2000-10-18 阿斯特拉公司 新的螺氮杂双环杂环化合物
CN1337964A (zh) * 1999-01-15 2002-02-27 阿斯特拉曾尼卡有限公司 治疗中有用的新的螺呋喃并吡啶芳烷基胺
WO2002096912A1 (en) * 2001-06-01 2002-12-05 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
US20030018042A1 (en) * 2001-06-01 2003-01-23 Phillips Eifion Spiro[1-azabicyclo[2.2.2.]octane-3,2'(3'h)-furo[2,3-b]pyridine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
KR20040099448A (ko) * 2002-04-18 2004-11-26 아스트라제네카 아베 티에닐 화합물
EP1499618B1 (en) * 2002-04-18 2010-10-13 AstraZeneca AB Furyl compounds
US7417050B2 (en) * 2002-04-18 2008-08-26 Astrazeneca Ab Heterocyclic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1270592A (zh) * 1997-07-18 2000-10-18 阿斯特拉公司 新的螺氮杂双环杂环化合物
CN1337964A (zh) * 1999-01-15 2002-02-27 阿斯特拉曾尼卡有限公司 治疗中有用的新的螺呋喃并吡啶芳烷基胺
WO2002096912A1 (en) * 2001-06-01 2002-12-05 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
US20030018042A1 (en) * 2001-06-01 2003-01-23 Phillips Eifion Spiro[1-azabicyclo[2.2.2.]octane-3,2'(3'h)-furo[2,3-b]pyridine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018210229A1 (zh) * 2017-05-18 2018-11-22 南京明德新药研发股份有限公司 α-7尼古丁乙酰胆碱受体激动剂及应用

Also Published As

Publication number Publication date
US7544693B2 (en) 2009-06-09
CA2543436A1 (en) 2005-05-12
EP1678183A1 (en) 2006-07-12
JP2007509121A (ja) 2007-04-12
JP4855264B2 (ja) 2012-01-18
NZ546413A (en) 2009-12-24
CN1871241A (zh) 2006-11-29
AU2004285751B2 (en) 2008-07-24
MXPA06004299A (es) 2006-06-05
AU2004285751A1 (en) 2005-05-12
US20070072887A1 (en) 2007-03-29
NO20062307L (no) 2006-07-19
IL174700A0 (en) 2006-08-20
BRPI0415546A (pt) 2006-12-26
WO2005042538A1 (en) 2005-05-12
KR20060094962A (ko) 2006-08-30

Similar Documents

Publication Publication Date Title
US7417049B2 (en) Furyl compounds
US7417050B2 (en) Heterocyclic compounds
US20110124672A1 (en) Thienyl Compounds
US6569865B2 (en) Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
CN100494202C (zh) 螺呋喃并吡啶芳基衍生物
HK1079522B (en) Thienyl compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090603

Termination date: 20121021